Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER-2 Gene Amplification”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT04785729
What this trial is testing

Almonertinib Combined With Pyrotinib in the Treatment of Advanced NSCLC Patients With HER-2 Amplification/Mutation After EGFR-TKI Resistance

Who this might be right for
Safety
Sun Yat-sen University 36
Testing effectiveness (Phase 2)Active Not RecruitingNCT06413745
What this trial is testing

Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer

Who this might be right for
HER2 Expression / Amplification in Patients With Biliary Tract Cancer
Jiangsu HengRui Medicine Co., Ltd. 59
Early research (Phase 1)Looking for participantsNCT07361562
What this trial is testing

A Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor, AdultERBB2 Altered Breast CancerERBB2 Gene Amplification+3 more
Cogent Biosciences, Inc. 100
Testing effectiveness (Phase 2)UnknownNCT05318339
What this trial is testing

Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma

Who this might be right for
Carcinoma, Transitional CellHER-2 Gene Amplification
Chinese Academy of Medical Sciences 30
Testing effectiveness (Phase 2)Looking for participantsNCT06749860
What this trial is testing

Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression

Who this might be right for
Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China 58
Testing effectiveness (Phase 2)Study completedNCT03783936
What this trial is testing

Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas

Who this might be right for
Gastric AdenocarcinomaEsophageal AdenocarcinomaMetastasis+1 more
Ashwin Somasundaram 18
Early research (Phase 1)Ended earlyNCT03065387
What this trial is testing

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

Who this might be right for
Advanced Malignant Solid NeoplasmEGFR Gene AmplificationEGFR Gene Mutation+7 more
M.D. Anderson Cancer Center 84
Not applicableLooking for participantsNCT06813456
What this trial is testing

Implementation of Solid Digital PCR to Support Gold-standard Methods for Evaluation of HER2 Amplification Status: Focus on HER2-low Subtype

Who this might be right for
Breast Cancer
IRCCS Azienda Ospedaliero-Universitaria di Bologna 234
Not applicableUnknownNCT03947736
What this trial is testing

Dynamic Monitoring of HER2 and ctDNA Specific Mutations in Patients With Recurrent or Metastatic Breast Cancer by Digital PCR

Who this might be right for
Recurrent or Metastatic Breast Cancer
Chinese Academy of Medical Sciences 200
Testing effectiveness (Phase 2)Ended earlyNCT00479856
What this trial is testing

Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer

Who this might be right for
Relapsed Breast CancerNeoplasms, Breast
GlaxoSmithKline 9
Early research (Phase 1)Ended earlyNCT04209465
What this trial is testing

BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.

Who this might be right for
Solid Tumor
Black Diamond Therapeutics, Inc. 91
Testing effectiveness (Phase 2)Looking for participantsNCT05315700
What this trial is testing

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Who this might be right for
Solid Tumors
ORIC Pharmaceuticals 350
Large-scale testing (Phase 3)Active Not RecruitingNCT05911295
What this trial is testing

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Who this might be right for
Urothelial Carcinoma
Seagen, a wholly owned subsidiary of Pfizer 412
Testing effectiveness (Phase 2)Looking for participantsNCT05867251
What this trial is testing

Study of AVZO-021 in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorHR+/HER2- Breast CancerHR+, HER2-, Advanced Breast Cancer+6 more
Avenzo Therapeutics, Inc. 430
Early research (Phase 1)Ended earlyNCT05252416
What this trial is testing

(VELA) Study of BLU-222 in Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsHR+ Breast CancerCCNE1 Amplification+6 more
Blueprint Medicines Corporation 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439110
What this trial is testing

Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 38
Testing effectiveness (Phase 2)Active Not RecruitingNCT05546268
What this trial is testing

Study of Oral MRT-2359 in Selected Cancer Patients

Who this might be right for
NSCLCSCLCHigh Grade Neuroendocrine Cancer+5 more
Monte Rosa Therapeutics, Inc 174
Testing effectiveness (Phase 2)Looking for participantsNCT07288359
What this trial is testing

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Who this might be right for
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsMetastatic Castration-resistant Prostate Cancer
Novartis Pharmaceuticals 205
Testing effectiveness (Phase 2)WithdrawnNCT05041972
What this trial is testing

ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)

Who this might be right for
HER2 Mutation-Related TumorsHER2 Amplified Solid Tumors
Ambrx, Inc.
Early research (Phase 1)Study completedNCT01304784
What this trial is testing

MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer

Who this might be right for
HER-2 Gene Amplification
Merrimack Pharmaceuticals 100
Next Page